12:00 AM
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD4547: Phase Ib/IIa started

Cancer Research UK (London, U.K) began a dose-finding, U.K. Phase Ib/IIa trial to evaluate AstraZeneca's AZD4547 plus cisplatin and capecitabine. The Phase Ib portion of the trial will enroll about 18 patients with solid tumors who will receive twice-daily AZD4547 and twice-daily capecitabine for the first 2 weeks of a...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >